What makes AT1R a challenging target for antibody discovery?

AT1R is a seven transmembrane GPCR with a complex membrane embedded structure. Maintaining its native conformation during immunization and screening requires specialized strategies. Creative Biolabs employs membrane protein stabilization techniques and cell based screening approaches to preserve the receptor natural epitopes, ensuring the identification of functionally relevant antibodies.

Can Creative Biolabs generate antibodies that distinguish between AT1R and other angiotensin receptors?

Yes. Through subtractive selection and epitope mapping strategies, we can enrich for antibodies that specifically recognize AT1R without cross reacting with AT2R or other related GPCRs. Our team designs custom screening protocols tailored to your specificity requirements.

What is the typical timeline for a custom anti-AT1R antibody discovery project?

Project timelines vary depending on the chosen strategy and antibody format. Generally, standard discovery programs range from 12 to 24 weeks from antigen preparation to initial candidate identification. We provide detailed project planning at the outset to align with your research timeline.

Do you offer both agonistic and antagonistic anti-AT1R antibodies?

Yes. Creative Biolabs supports the discovery of both agonistic autoantibodies and antagonistic antibodies. Our screening platforms are designed to select for specific functional properties, including receptor activation, inhibition, or allosteric modulation, based on your research objectives.

Anti-AT1R Antibody Introduction

Overview Background Applications Our Platform Our Services FAQs

Overview of Anti-AT1R Antibody

Fig.1 Structure of AT1R. (Creative Biolabs Authorized)

The anti-angiotensin II type 1 receptor (AT1R) antibody is an indispensable tool for dissecting the pathological and physiological functions of AT1R, a member of the G protein-coupled receptor family. AT1R is widely distributed in the kidney, heart, vascular smooth muscle cells, adrenal cortex, brain, platelets and placenta. As the dominant receptor for angiotensin II in the glomerulus, it tightly governs arterial blood pressure, water and salt homeostasis, and intracellular stability. Its excessive activation drives hypertension, vasoconstriction, and vascular smooth muscle migration and proliferation. Critically, AT1R autoantibodies (AT1R-AA) have emerged as key players in preeclampsia, malignant hypertension and renal transplant vascular rejection. Creative Biolabs delivers an integrated, end-to-end solution covering custom agonistic antibody and agonistic autoantibody discovery, engineering and functional validation, empowering your research with precise and reliable molecular tools.

Scientific Background of AT1R

AT1R orchestrates multiple cardiovascular and renal processes. Its primary physiological effects encompass stimulation of cardiomyocyte growth and positive inotropic action, promotion of vascular smooth muscle cell division and proliferation, induction of vasoconstriction, sympathetic nerve activation with enhanced catecholamine release, secretion of antidiuretic hormone and aldosterone, and regulation of water intake and urinary sodium excretion. These actions collectively elevate blood pressure and sustain fluid homeostasis.

Beyond these physiological roles, AT1R autoantibodies target the second extracellular loop of the receptor, triggering cell proliferation, hypertrophy, vasoconstriction, and profound remodeling of the vascular wall and target organs. Animal immunization studies directly demonstrate that AT1 antibodies stimulate smooth muscle cell proliferation and cause vascular wall thickening and restructuring, underpinning their pathogenic role in hypertensive disorders. In vascular smooth muscle cells, AT1R autoantibodies upregulate transcription activators such as NF-κB and AP-1, which in turn drive nuclear expression of c-Jun, c-Fos and other regulatory genes. These findings confirm that AT1R autoantibodies exert angiotensin II-like agonist effects, strongly implicating them in the development of hypertension, preeclampsia and other AT1R-antibody-positive conditions.

Targeting AT1R autoantibodies with agonistic antibody based strategies represent a promising therapeutic frontier. AT1R is firmly established as a major target for cardiovascular drug development, and antibody modalities offer distinct advantages over small molecule angiotensin receptor blockers (ARBs) in terms of target specificity and pregnancy safety.

Anti-AT1R Antibody Applications Across Therapeutic Areas

Cardiovascular Disease Investigation

Anti AT1R antibodies are essential for deciphering the molecular basis of hypertension, atherosclerosis and cardiac remodeling. AT1R-AAs have been detected in patients with preeclampsia, essential hypertension, atherosclerotic disease and heart transplant rejection, making these antibodies critical for mechanistic and biomarker studies.

Renal Disease and Transplant Rejection

AT1R antibodies identify kidney transplant recipients at elevated risk for HLA independent allograft rejection and loss. Anti AT1R antibody testing now serves as a vital biomarker for post-transplant risk stratification.

Tumor Microenvironment Research

AT1R expression is upregulated in multiple malignancies, where its activation accelerates cancer progression. Inhibition with ARBs suppresses tumor growth and induces apoptosis. Antibody based AT1R inhibitors therefore open novel avenues for cancer therapy.

Pregnancy Associated Disorders

Approximately 80% of preeclampsia patients present elevated maternal serum AT1R-AA concentrations at diagnosis, and the antibody levels correlate positively with the severity of hypertension and proteinuria. Anti AT1R antibodies offer a powerful entry point for investigating hypertensive disorders of pregnancy.

Consult with Our Experts to Evaluate Your Target Strategy

The Creative Biolabs Antibody Discovery Platform

Creative Biolabs operates a fully integrated antibody discovery engine that ensures success with challenging targets like AT1R. Our platform encompasses antigen design, immunization, library construction, high throughput screening, affinity maturation and humanization. We support the generation of monoclonal antibodies, polyclonal antibodies, bispecific antibodies and VHHs. Advanced orthogonal methods, including specific affinity extraction and optimization, guarantee candidates with superior binding properties. For GPCR targets such as AT1R, our specialized membrane protein stabilization techniques and cell based screening strategies preserve native epitope conformation. All workflows are governed by a quality system aligned with regulatory expectations, delivering customized, validation ready anti AT1R antibodies.

Advance Your Project on Our Professional Platform

Integrated Services for Anti-AT1R Antibody Discovery

Fig.2 Antibody Discovery Research Discussion. (Creative Biolabs AI)

The pathogenic significance of anti-AT1R antibodies has been unequivocally established across multiple vascular pathologies. In renal transplantation, elevated anti-AT1R antibody titers are strongly implicated in antibody-mediated rejection, even in the absence of donor-specific HLA antibodies. In heart transplantation, increased anti-AT1R antibody levels correlate with both cell-mediated and antibody-mediated rejection, as well as the early onset of transplant vasculopathy. The synergistic influence of high-titered AT1R antibodies and HLA class II donor-specific antibodies has been proposed to contribute to antibody-mediated rejection in kidney transplantation. This process may also exacerbate hypertensive complications in susceptible recipients. Furthermore, the transplantation process itself may upregulate AT1R expression, thereby amplifying the pathogenic impact of these antibodies on activated vascular cells, while ischemia-reperfusion injury can trigger oxidative stress and innate immune responses that contribute to alloantigen recognition.

Creative Biolabs has strategically positioned our expertise at the forefront of agonistic autoantibody research. We recognize that anti-AT1R antibodies, which are directed against the second extracellular loop of the receptor, may arise through both autoreactive and alloreactive mechanisms. Inflammatory events and tissue injury can lead to de novo expression of these autoantigens, making their detection and characterization essential for comprehensive immunological risk assessment in transplant recipients.

Our integrated service framework is designed to support the entire continuum of anti-AT1R antibody projects, from initial discovery to advanced characterization. We offer:

1. Custom Anti-AT1R Antibody Generation

We employ proven agonistic antibody development platforms to generate high-quality, specific antibodies against AT1R. Our end-to-end solutions encompass design, development, and final delivery, ensuring that each antibody meets the rigorous demands of preclinical research and clinical applications.

2. Comprehensive Characterization and Testing

Our services include robust process monitoring and characteristic testing tailored to anti-AT1R antibodies. We utilize state-of-the-art orthogonal methods, including but not limited to antibody affinity extraction, affinity maturation, and antibody humanization, to ensure that your antibodies meet regulatory and performance standards.

3. Transplant Immunology Support

We provide specialized support for evaluating the role of anti-AT1R antibodies in renal and thoracic transplantation. By integrating AT1R antibody profiling with HLA assessment, we help determine the comprehensive immunological risk for transplant recipients, enabling more informed clinical decision-making.

4. Pathophysiological Mechanism Investigation

Our team offers deep expertise in the pathophysiological mechanisms of agonistic autoantibodies, assisting clients in exploring the molecular pathways through which anti-AT1R antibodies exert their effects, from receptor activation to downstream signaling and tissue remodeling.

Come Here to Discuss Your Project

FAQs

Q: What makes AT1R a challenging target for antibody discovery?
A: AT1R is a seven transmembrane GPCR with a complex membrane embedded structure. Maintaining its native conformation during immunization and screening requires specialized strategies. Creative Biolabs employs membrane protein stabilization techniques and cell based screening approaches to preserve the receptor natural epitopes, ensuring the identification of functionally relevant antibodies.
Q: Can Creative Biolabs generate antibodies that distinguish between AT1R and other angiotensin receptors?
A: Yes. Through subtractive selection and epitope mapping strategies, we can enrich for antibodies that specifically recognize AT1R without cross reacting with AT2R or other related GPCRs. Our team designs custom screening protocols tailored to your specificity requirements.
Q: What is the typical timeline for a custom anti-AT1R antibody discovery project?
A: Project timelines vary depending on the chosen strategy and antibody format. Generally, standard discovery programs range from 12 to 24 weeks from antigen preparation to initial candidate identification. We provide detailed project planning at the outset to align with your research timeline.
Q: Do you offer both agonistic and antagonistic anti-AT1R antibodies?
A: Yes. Creative Biolabs supports the discovery of both agonistic autoantibodies and antagonistic antibodies. Our screening platforms are designed to select for specific functional properties, including receptor activation, inhibition, or allosteric modulation, based on your research objectives.

Partner with Our Scientists to Transform Your Challenges

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: